Cargando…
An Update on Blood-Based Markers of Alzheimer’s Disease Using the SiMoA Platform
The development of blood-based biomarkers of Alzheimer’s disease (AD) pathology as tools for screening the general population, and as the first step in a multistep process to determine which non-demented individuals are at greatest risk of developing AD dementia, is essential. Proteins that are refl...
Autores principales: | Li, Danni, Mielke, Michelle M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6908531/ https://www.ncbi.nlm.nih.gov/pubmed/31833025 http://dx.doi.org/10.1007/s40120-019-00164-5 |
Ejemplares similares
-
Fast quantification of extracellular vesicles levels in early breast cancer patients by Single Molecule Detection Array (SiMoA)
por: Morasso, Carlo, et al.
Publicado: (2021) -
Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer’s disease
por: Nilsson, Johanna, et al.
Publicado: (2022) -
Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis
por: De Meyer, Steffi, et al.
Publicado: (2020) -
Correlational Analysis of ALS Progression and Serum NfL Measured by Simoa Assay in Chinese Patients
por: Sugimoto, Kazuo, et al.
Publicado: (2020) -
Comparison of Simoa(TM) and Ella(TM) to assess serum neurofilament‐light chain in multiple sclerosis
por: Gauthier, Audrey, et al.
Publicado: (2021)